Department of Neurology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China.
Department of Neurology, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shanxi, People's Republic of China.
Clin Interv Aging. 2020 Aug 4;15:1285-1294. doi: 10.2147/CIA.S230186. eCollection 2020.
Interleukin-37 is a novel cytokine emerging as a natural suppressor of inflammatory responses. Inflammation and the immune response play important roles in acute ischemic stroke. This study aimed at evaluating the plasma levels and the association with 3-month outcomes of interleukin-37 in acute ischemic stroke patients.
In total, 152 consecutive patients with acute ischemic stroke and 45 healthy controls were included. Plasma interleukin-37 levels were determined in the first morning after admission using an enzyme-linked immunesorbent assay. The primary outcome was the 3-month functional outcome (modified Rankin Scale score >2). Logistic regression was used to evaluate the risk and 3-month outcome of stroke according to plasma interleukin-37 level.
Plasma interleukin-37 levels were significantly higher in the patients with acute ischaemic stroke than in the healthy controls (182.26 versus 97.89 pg/mL, <0.001). Patients with large-artery atherosclerosis had significantly higher IL-37 levels than those with small-artery occlusion (202.12±35.82 versus 175.67±33.71pg/mL, <0.001). Plasma interleukin-37 levels were positively correlated with National Institutes of Health Stroke Scale scores (r=0.521, <0.0001) and lesion volume (r=0.442, <0.0001). Ninety-four and 58 patients had favourable and unfavourable 3-month outcomes, respectively. Elevated plasma interleukin-37 levels were independently associated with unfavourable 3-month outcomes (adjusted odds ratio=1.033, =0.001, 95% confidence interval: 1.015-1.056).
Admission plasma interleukin-37 levels were significantly increased after acute ischemic stroke. Elevated interleukin-37 levels were independently associated with unfavourable 3-month prognoses in acute ischemic stroke patients. Further studies with other populations are needed.
白细胞介素-37 是一种新出现的细胞因子，作为炎症反应的天然抑制剂。炎症和免疫反应在急性缺血性中风中起着重要作用。本研究旨在评估急性缺血性中风患者的白细胞介素-37 血浆水平及其与 3 个月预后的关系。
共纳入 152 例连续急性缺血性中风患者和 45 例健康对照者。采用酶联免疫吸附试验测定入院后第一个早晨的血浆白细胞介素-37 水平。主要结局为 3 个月时的功能结局（改良 Rankin 量表评分＞2）。采用 logistic 回归评估根据血浆白细胞介素-37 水平的卒中风险和 3 个月预后。
急性缺血性中风患者的血浆白细胞介素-37 水平明显高于健康对照组（182.26 与 97.89pg/ml，＜0.001）。大动脉粥样硬化患者的白细胞介素-37 水平明显高于小动脉闭塞患者（202.12±35.82 与 175.67±33.71pg/ml，＜0.001）。血浆白细胞介素-37 水平与国立卫生研究院卒中量表评分呈正相关（r=0.521，＜0.0001），与病变体积呈正相关（r=0.442，＜0.0001）。94 例和 58 例患者的 3 个月预后分别为良好和不良。入院时血浆白细胞介素-37 水平升高与 3 个月预后不良独立相关（调整后的优势比=1.033，=0.001，95%置信区间：1.015-1.056）。
急性缺血性中风后，白细胞介素-37 水平明显升高。入院时白细胞介素-37 水平升高与急性缺血性中风患者 3 个月预后不良独立相关。需要对其他人群进行进一步研究。
